CXCL9 and neoplasm: CEA-TCB-treated tumors displayed a clear upregulation of several pro-inflammatory cytokines and chemokines [MIPα (CCL3), CXCL10, CXCL13, CXCL9, IL-16, and I-TAC (CXCL11)], an increase in intra-tumor CD3+, CD4+, CD8+ T-cells that express high levels of 4-1BB, PD-1, and upregulation of GZMB (Figure 2A).